Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease

Brain

Volumn 123, Issue 7, 2000, Pages 1365-1379

  Lee, Chong S ^a,c   Cenci, M Angela ^b   Schulzer, Michael ^a   Björklund, Anders ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b LUND UNIVERSITY   (Sweden)

^c Neurodegenerative Disorders Centre   (Canada)

Author keywords

6 OHDA; Embryonic dopamine neuronal graft; Levodopa induced dyskinesia; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; LIGAND; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN; PRODYNORPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN GRAFT; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DISEASE MARKER; DISEASE SEVERITY; DYSKINESIA; EMBRYONAL TISSUE; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVOLUNTARY MOVEMENT; MESENCEPHALON; NERVE CONDUCTION; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTYPY;

EID: 0033932460     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.7.1365     Document Type: Article

References (73)

1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. [Review]. Annu Rev Neurosci 1986; 9: 357-81.
2. Amalric M, Koob GF. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. [Review]. Prog Brain Res 1993; 99: 209-26.
3. Bal A, Savasta M, Chritin M, Mennicken F, Abrous DN, Le Moal M, et al. Transplantation of fetal nigral cells reverses the increase of preproenkephalin mRNA levels in the rat striatum caused by 6-OHDA lesion of the dopaminergic nigrostriatal pathway: a quantitative in situ hybridization study. Brain Res Mol Brain Res 1993; 18: 221-7.
4. 3H]spiperone binding. Brain Res 1986; 379: 294-9.
5. Bjorklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol Scand Suppl 1983; 522: 9-18.
6. Blunt S, Jenner P, Marsden CD. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience 1991; 40: 453-64.
7. Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990; 13: 448-58.
8. Brotchie JM. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia. [Review]. Adv Neurol 1999; 80: 71-85.
9. Cadet JL, Zhu SM, Angulo JA. Intrastriatal implants of fetal mesencephalic cells attenuate the increases in striatal proenkephalin mRNA observed after unilateral 6-hydroxydopamine-induced lesions of the striatum. Brain Res Bull 1991; 27: 707-11.
10. Cenci MA, Campbell K, Bjorklund A. Glutamic acid decarboxylase gene expression in the dopamine-denervated striatum: effects of intrastriatal fetal nigral transplants or chronic apomorphine treatment. Brain Res Mol Brain Res 1997; 48: 149-55.
11. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphinand glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10: 2694-706.
12. Chesselet MF, Mercugliano M, Soghomonian JJ, Salin P, Qin Y, Gonzales C. Regulation of glutamic acid decarboxylase gene expression in efferent neurons of the basal ganglia. [Review]. Prog Brain Res 1993; 99: 143-54.
13. Chritin M, Blanchard V, Raisman-Vozari R, Feuerstein C, Agid Y, Javoy-Agid F, et al. DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration. Eur J Neurosci 1996; 8: 2511-20.
14. Civelli O, Douglass J, Goldstein A, Herbert E. Sequence and expression of the rat prodynorphin gene. Proc Natl Acad Sci USA 1985; 82: 4291-5.
15. Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1989; 90: 307-14.
16. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9.
17. Crossman AR, Sambrook MA, Jackson A. Experimental hemichorea/ hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain 1984; 107: 579-96.
18. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996; 119: 41-50.
19. Delfs JM, Ciaramitaro VM, Parry TJ, Chesselet MF. Subthalamic nucleus lesions: widespread effects on changes in gene expression induced by nigrostriatal dopamine depletion in rats. J Neurosci 1995; 15: 6562-75.
20. DeLong MR, Georgopoulos AP, Crutcher MD, Mitchell SJ, Richardson RT, Alexander GE. Functional organization of the basal ganglia: contributions of single-cell recording studies. In: Evered D, O'Connor M, editors. Functions of the basal ganglia. Ciba Foundation Symposium, Vol. 107. London: Pitman; 1984. p. 64-82.
21. Dewar D, Jenner P, Marsden CD. Effects of opioid agonist drugs on the in vitro release of 3H-GABA, 3H-dopamine and 3H-5HT from slices of rat globus pallidus. Biochem Pharmacol 1987; 36: 1738-41.
22. Dickson PR, Lang CG, Hinton SC, Kelley AE. Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study. Neuroscience 1994; 61: 81-91.
23. Dunnett SB, Bjorklund A, Schmidt RH, Stenevi U, Iversen SD. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand Suppl 1983; 522: 29-37.
24. Dunnett SB, Whishaw IQ, Rogers DC, Jones GH. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions. Brain Res 1987; 415: 63-78.
25. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997; 144: 423-32.
26. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113-8.
27. Filloux F, Hunt MA, Wamsley JK. Localization of the dopamine uptake complex using [3H]N-[1-(2-benzo(b)thiophenyl)cyclohexyl]-piperidine ([3H]BTCP) in rat brain. Neurosci Lett 1989; 100: 105-10.
28. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-32.
29. Howells RD, Kilpatrick DL, Bhatt R, Monahan JJ, Poonian M, Udenfriend S. Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues. Proc Natl Acad Sci USA 1984; 81: 7651-5.
30. Hughes AJ, Frankel JP, Kempster PA, Stern GM, Lees AJ. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994; 57: 430-4.
31. Jiang ZG, North RA. Pre- and postsynaptic inhibition by opioids in rat striatum. J Neurosci 1992; 12: 356-61.
32. Kelley AE, Gauthier AM, Lang CG. Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior. Behav Brain Res 1989; 35: 27-39.
33. Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 1975; 94: 507-22.
34. Kempster PA, Gibb WR, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989; 52: 72-6.
35. Kincaid AE, Albin RL, Newman SW, Penney JB, Young AB. 6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamate decarboxylase messenger RNA in rat globus pallidus projection neurons. Neuroscience 1992; 51: 705-18.
36. Kobayashi Y, Kaufman DL, Tobin AJ. Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein. J Neurosci 1987; 7: 2768-72.
37. Koob GF, Simon H, Herman JP, Le Moal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems. Brain Res 1984; 303: 319-29.
38. Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. Cell Transplant 1996; 5: 327-37.
39. Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp Neurol 1997; 146: 536-45.
40. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-24.
41. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998; 13: 383-93.
42. Lavin A, Garcia-Munoz M. Electrophysiological changes in substantia nigra after dynorphin administration. Brain Res 1986; 369: 298-302.
43. Li SJ, Sivam SP, McGinty JF, Jiang HK, Douglass J, Calavetta L, et al. Regulation of the metabolism of striatal dynorphin by the dopaminergic system. J Pharmacol Exp Ther 1988; 246: 403-8.
44. Li SJ, Jiang HK, Stachowiak MS, Hudson PM, Owyang V, Nanry K, et al. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Brain Res Mol Brain Res 1990; 8: 219-25.
45. Lindvall O. Clinical application of neuronal grafts in Parkinson's disease. [Review]. J Neurol 1994; 242 (1 Suppl 1): S54-6.
46. Lindvall O. Update on fetal transplantation: the Swedish experience. [Review]. Mov Disord 1998; 13 Suppl 1: 83-7.
47. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615-31.
48. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-65.
49. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
50. Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994; 125: 65-71.
51. Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res 1995; 683: 102-8.
52. Marin C, Chase TN. Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors. Neuropharmacology 1995; 34: 677-82.
53. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD and Fahn S, editors. Movement disorders. London: Butterworth; 1982. p. 96-122.
54. Matsumoto RR, Brinsfield KH, Patrick RL, Walker JM. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists. J Pharmacol Exp Ther 1988; 246: 196-203.
55. Matsumura M, Tremblay L, Richard H, Filion M. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience 1995; 65: 59-70.
56. Mendez IM, Naus CC, Elisevich K, Flumerfelt BA. Normalization of striatal proenkephalin and preprotachykinin mRNA expression by fetal substantia nigra grafts. Exp Neurol 1993; 119: 1-10.
57. Miller JA. The calibration of 35S or 32P with 14C-labeled brain paste or 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neurosci Lett 1991; 121: 211-4.
58. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 668-73.
59. Nakao N, Ogura M, Nakai K, Itakura T. Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease. J Neurosci 1998; 18: 1806-17.
60. Normand E, Popovici T, Onteniente B, Fellmann D, Piatier-Tonneau D, Auffray C, et al. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res 1988; 439: 39-46.
61. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. [Review]. Neurology 1990; 40: 340-5.
62. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd edn. San Diego: Academic Press; 1986.
63. Peschanski M, Defer G, N'Guyen JP. Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-99.
64. Rebec GV, Bashore TR. Critical issues in assessing the behavioral effects of amphetamine. Neurosci Biobehav Rev 1984; 8: 153-79.
65. Roy E, Cote PY, Gregoire L, Parent A, Bedard PJ. Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxy-dopamine-lesioned rats treated chronically with L-dihydroxy-phenylalanine. Neuroscience 1995; 66: 413-25.
66. Scheel-Kruger J. GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions. [Review]. Adv Neurol 1984; 40: 85-90.
67. Schmidt RH, Ingvar M, Lindvall O, Stenevi U, Bjorklund A. Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C]2-deoxy-D-glucose autoradiography. J Neurochem 1982; 38: 737-48.
68. Schmidt RH, Bjorklund A, Stenevi U, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl 1983; 522: 19-28.
69. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 1987; 401: 322-30.
70. Thompson LA, Walker JM. Inhibitory effects of the kappa opiate U50,488 in the substantia nigra pars reticulata. Brain Res 1990; 517: 81-7.
71. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-93.
72. Vignon J, Pinet V, Cerruti C, Kamenka JM, Chicheportiche R. [3H]N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine ([3H]BTCP): a new phencyclidine analog selective for the dopamine uptake complex. Eur J Pharmacol 1988; 148: 427-36.
73. Walters AS, McHale D, Sage JI, Hening WA, Bergen M. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea. Clin Neuropharmacol 1990; 13: 236-40.